RENAL DISEASE IN DOGS AND CATS: THE IMPORTANCE OF EARLY DETECTION AND WHY PHOSPHATE BINDERS MATTER

Chronic kidney disease (CKD) remains one of the most prevalent and clinically challenging conditions in small animal practice, particularly in ageing feline patients, with prognosis closely linked to the timing of diagnosis and metabolic control. The kidneys play a central role in maintaining metabolic homeostasis, including waste excretion, electrolyte balance, blood pressure regulation, and fluid equilibrium. Progressive renal dysfunction therefore results in widespread systemic consequences.

In pets, renal disease may develop suddenly (acute kidney injury) or gradually over time. CKD is especially common in older cats. Pathophysiologically, CKD is characterised by progressive, irreversible loss of functional nephrons. Clinical signs typically manifest only after approximately 66–75% of nephron function has been lost, making reliance on overt symptoms (increased thirst, more frequent urination, weight loss, reduced appetite, lethargy, or occasional vomiting) a late-stage indicator of disease. Consequently, proactive screening is essential.

The Critical Role of Annual Blood Testing

Because early CKD is frequently subclinical, annual blood testing (biochemistry and SDMA), urinalysis, urine protein:creatinine ratio, and blood pressure measurement should be considered minimum preventive screening in adult pets — and ideally every 6 months in senior and geriatric patients.

Early biochemical changes often precede obvious clinical signs by months to years. Identifying mild elevations in creatinine, SDMA, early proteinuria, or rising phosphate levels allows intervention during the earliest phases of disease, when nephron loss is still partially compensable.

Regular screening enables:

• Early IRIS staging

• Timely dietary intervention

• Blood pressure control

• Monitoring of proteinuria

• Early phosphate management

• Slowing of disease progression

  
  

Without routine testing, CKD is frequently diagnosed only at advanced stages, when therapeutic options are more limited and prognosis is guarded.

What If Owners Decline Blood Testing?

In real-world practice, financial, emotional, or compliance barriers may prevent annual screening. While diagnostics remain the gold standard, clinicians must still prioritise nephron preservation and metabolic control whenever CKD is suspected or previously documented.

One of the most clinically significant and modifiable drivers of progression is phosphate retention.

Hyperphosphataemia is a predictable and clinically significant consequence of declining glomerular filtration rate (GFR) in canine and feline CKD. As nephron mass decreases, phosphorus excretion becomes inadequate, leading to phosphate retention, secondary hyperparathyroidism, and progression of renal secondary hyperparathyroidism (RSHPT). Importantly, phosphate retention begins before overt hyperphosphataemia is always evident on routine panels. For this reason, early phosphate control is protective, not merely reactive.

Why Early Phosphate Control Matters — Even in Early IRIS Stages

According to the staging framework established by the International Renal Interest Society (IRIS), phosphate targets are stage-specific and should be maintained within defined limits to slow disease progression.

Even in early IRIS stages (Stage 1–2):

• Phosphate retention contributes to nephron injury

• Fibroblast growth factor-23 (FGF-23) rises early

• Secondary hyperparathyroidism may begin before overt hyperphosphataemia

• Progressive renal mineral and bone disorder (CKD-MBD) can develop

  
  

Waiting for marked hyperphosphataemia before intervention allows ongoing metabolic damage.

When renal diets are not accepted, inconsistently fed, or insufficient to maintain phosphate within IRIS targets, intestinal phosphate binders should be introduced early rather than delayed.

Early use in appropriate cases can:

• Reduce intestinal phosphate absorption

• Support maintenance within IRIS phosphate targets

• Limit renal secondary hyperparathyroidism

• Reduce soft tissue mineralisation risk

• Potentially slow progression of nephron loss

  
  

Dietary Management and the Role of Phosphate Binders

Dietary phosphate restriction remains first-line therapy and is strongly supported by survival data, particularly in feline CKD. However, compliance can be variable, and some patients remain above target phosphate levels despite appropriate renal diets. In these cases, intestinal phosphate binders are not optional adjuncts — they are a core component of metabolic control.

EasyPill Rena Expert is a palatable nutritional supplement formulated to support the medical management of canine and feline CKD. Designed to assist with intestinal phosphate binding, it helps reduce dietary phosphorus absorption, supporting serum phosphate control within IRIS stage-specific targets. Effective phosphate management is critical in limiting renal secondary hyperparathyroidism, soft tissue mineralisation, and progression of nephron loss. Its highly palatable matrix promotes reliable voluntary intake, improving compliance in long-term cases where dietary management alone is insufficient. As part of a multimodal CKD protocol, it supports metabolic stability and sustained phosphate regulation.

In conclusion, CKD is both common and frequently clinically silent in its early stages, making routine annual blood and urine screening essential for timely detection. Waiting for overt clinical signs inevitably delays intervention and limits therapeutic impact. Phosphate retention plays a central role in disease progression, beginning early during CKD, which underscores the importance of proactive phosphate control rather than reactive management. Early-stage phosphate regulation is protective and evidence-based, not excessive. When dietary management alone is insufficient — or when full diagnostics are not feasible — the early introduction of intestinal phosphate binders represents a rational, nephron-sparing strategy. Ultimately, proactive monitoring and early metabolic intervention remain our most effective tools for preserving renal function and extending quality of life in canine and feline CKD patients.